MEDFORD, Mass. – Myrobalan Therapeutics, a biotechnology company developing potent, selective, and brain-penetrant oral small-molecule therapies to restore brain function, today announced a grant of over $850,000 from the National Multiple Sclerosis Society to support the preclinical and translational development of MRO-002, a G-protein-coupled receptor 17 (GPR17) antagonist, for the...

CAMBRIDGE, Mass. — Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, is launching a new project focused on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer. The effort will engage with tRCC patients,...

FREDERICK, Md. and MINNEAPOLIS, Minn. — TeleRare Health™ launched a partnership today with a leading community health system in Maryland, with a focus on expanding patient access to genetic testing, diagnosis, and knowledgeable care for rare and genetics-based diseases. In the United States, a disease is considered rare if it...